XO Life
XO Life operates brite™, a B2B SaaS meta-platform that connects pharmaceutical and medical device manufacturers with patients for digital therapy support, real-world evidence collection, pharmacovigilance digitization, and patient-reported outcomes across 40+ indications, serving 30+ manufacturers including Pfizer, Moderna, and Vertex.
- Company typePrivate
- Founded2017
- HeadquartersMünchen, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What XO Life does
XO Life operates the brite™ meta-platform, a B2B SaaS digital health solution that connects pharmaceutical and medical device manufacturers with patients through a single unified application. Founded in 2017 in Munich as Medikura, the company rebranded to XO Life in 2021 and relaunched its ImpactMonitor platform as brite™ in January 2025 to support international expansion. The platform delivers digital product and therapy companions, verified medical content, pharmacovigilance reporting, and real-world evidence collection, organized into four integrated modules: Product and Therapy Areas (brite Spaces), Real World Data, Pharmacovigilance, and Publisher Account. The general indication content area is co-developed with leading research institutes including the Charité PROMIS Institute, lending scientific credibility to standardized patient-reported outcome measures. XO Life claims a 60% patient response rate (approximately 10x industry average), 95% time savings in pharmacovigilance processes, and 90% cost savings versus proprietary app development.
The platform covers 40+ indications and partners with more than 30 pharmaceutical and medical device manufacturers, including Pfizer, Moderna, Vertex, Gilead, Novo Nordisk, Bionorica, Weleda, Medice, Glenmark, AAA-Pharma, and Ardeypharm. Distribution channels combine direct enterprise sales (led by Chief Client Officer Zdenka Vesely), research institution partnerships (Charité, EORTC), and clinician-mediated channels such as the nationwide agreement with Germany's Federal Association of Pulmonologists (BdP) for asthma and COPD support.
The business model is enterprise SaaS subscription with multi-year contracts, supplemented by managed digital patient support services. Revenue is generated from pharmaceutical and medical device manufacturers paying for platform access and digital engagement services. The company has raised approximately €13 million across three funding rounds (February 2022: €2M; August 2024: €7M; April 2026: €4M), with the most recent round led by Fil Rouge Capital to accelerate European expansion and AI capability scaling. The leadership team is founder-led by Dr. Friderike Bruchmann (CEO) with a CTO hire in June 2025 (Sergey Vasilyev, ex-Flo Health VP Engineering), a Chief Client Officer, and a Chief Strategy Officer/VP Client Partnerships focused on international growth.
XO Life firmographics
Firmographics- Name
- XO Life
- Legal name
- XO Life GmbH
- Website
- https://xo-life.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- XO Life operates brite™, a B2B SaaS meta-platform that connects pharmaceutical and medical device manufacturers with patients for digital therapy support, real-world evidence collection, pharmacovigilance digitization, and patient-reported outcomes across 40+ indications, serving 30+ manufacturers including Pfizer, Moderna, and Vertex.
- Ownership category
- akta.pro rank
XO Life industry classification
Industry- Product category
- Digital Health Patient Engagement Platform
- NAICS
- Software Publishers (51321)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where XO Life is headquartered
LocationHeadquarters
- HQ city
- München
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
XO Life business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- SaaS Platform Subscription: XO Life offers its brite™ platform technology as a Software-as-a-Service solution to pharmaceutical companies. Manufacturers pay for access to provide digital patient support, therapy monitoring, and real-world data collection capabilities for their products and therapy areas.
- Digital Patient Support Services: Revenue generated from providing digital therapy support and patient engagement services to pharmaceutical and medical device manufacturers across their product portfolios.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform access for pharmaceutical manufacturers |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
XO Life product offering
Product offeringCore offering
XO Life operates the brite™ meta-platform, a one-stop B2B SaaS solution that connects pharmaceutical and medical device manufacturers with patients to deliver digital product and treatment support. Manufacturers receive their own branded product areas within a single unified app, enabling therapy monitoring, patient-reported outcomes (PRO) collection, pharmacovigilance reporting, and real-world evidence generation across more than 40 indications.
Product overview
XO Life operates as a platform-plus-modules architecture centered on the brite™ meta-platform (formerly ImpactMonitor™), a globally unique one-stop digital patient support solution. The platform unifies pharmaceutical and medical device manufacturers with patients through a single app, offering personalized digital therapy support, verified medical content, and real-world evidence collection. The core product is supplemented by four integrated modules: Product and Therapy Areas (brite Spaces) for manufacturer-specific digital companions, Real World Data for patient-reported outcome analytics, Pharmacovigilance for digitized adverse event reporting, and Publisher Account for health content publishing. The platform also includes a General Indication Area developed with Charité research institute, Patient-Reported Outcome Measures (PROMs), and the MedWatcher drug safety sub-brand. The system collects patient experiences in structured, validated formats for use by healthcare stakeholders while enabling 95% process automation in pharmacovigilance workflows.
Differentiator
Problem solved
Functional benefit
Brands
- brite: Digital therapy support meta-platform that provides verified medical information, therapy monitoring, and patient support. The platform connects pharma companies with patients to offer personalized digital treatment companions.
- ImpactMonitor
- MedWatcher
Products and services
- brite™ Platform A globally unique meta-platform serving as a one-stop shop that brings together pharmaceutical and medical device manufacturers to offer patients digital product or treatment support within a single unified app. Eliminates the need for separate proprietary apps per product.
- Product and Therapy Areas (brite Spaces)
Quantifiable outcome
- 60% patient response rate, approximately 10x industry average
- +5 more outcomes
Companies that use XO Life
Customer profileNamed customers15 records
Segments4 records
Ideal customer profiles2 records
XO Life technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability6 records
Feature6 records
XO Life partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Germany's Federal Association of Pulmonologists (BdP)flagshipNationwide cooperation launched June 2026 to support asthma and COPD patients digitally through brite platform. After successful pilot, brite is now available free to patients across Germany through pulmonologists.
- EORTCcoreEuropean Organisation for Research and Treatment of Cancer partnered with XO Life to create access to valuable feedback from cancer patients for research through MedWatcher platform.
- Charité PROMIS InstitutecoreLeading European research institute collaborated with XO Life to develop standardized questionnaires for patient-reported outcomes (PRO). Partnership enables scientific rigor and credibility for outcome measurement.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
XO Life competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Largest global healthcare data and clinical research services company with extensive real-world evidence, pharmacovigilance, and patient engagement offerings sold to the same pharma and medical device manufacturers that XO Life targets.
- Veeva Systems: Enterprise cloud software provider to the global life sciences industry; its Veeva Vault and CDB offerings compete for the same pharma customer budget allocated to digital patient and RWE infrastructure.
Direct peers
- Medable: Decentralized clinical trial and patient engagement platform that captures eCOA/PRO data from patients and delivers it to pharma sponsors, directly overlapping XO Life's PRO, RWE, and pharma SaaS value proposition.
- Science 37: Decentralized clinical trial operator with a patient-facing app for eConsent, eCOA, and engagement; addresses the same pharma-sponsored patient experience workflows as XO Life's brite™.
- Evidation Health: Patient-generated health data platform that connects individuals, researchers, and pharma companies for real-world evidence generation — overlapping XO Life's RWE and patient engagement positioning.
- smartpatient (MyTherapy): Munich-based digital health company behind the MyTherapy patient medication adherence app, with pharma-sponsored content areas and pharmacovigilance integrations — a near-direct European competitor to brite™.
- PatientsLikeMe: Patient network and real-world health data platform that aggregates patient-reported outcomes for research and pharma R&D — comparable to XO Life's PRO and RWE data licensing value proposition.
Emerging players
- Castor: Cloud platform for clinical trial data capture including ePRO/eCOA, targeting pharma and CRO customers; competes with XO Life on patient-reported outcomes collection and real-world data structuring.
- uMotif: Patient-centric eCOA and electronic informed consent platform used by pharma sponsors across clinical and real-world studies, competing for the same pharma budget allocated to patient data capture.
- Curebase: Decentralized clinical trial software provider offering ePRO, eConsent, and remote patient engagement tools to pharma sponsors, with partial overlap with XO Life's patient engagement modules.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
XO Life social profiles
Digital presenceXO Life compliance and trust
Trust signalCompliance1 record
XO Life financial estimates
Financial estimateRevenue estimate
Valuation estimate
XO Life leadership team
Management profileNumber of profiles
Profiles5 records
XO Life funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
XO Life M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about XO Life
What does XO Life do?
XO Life operates the brite™ meta-platform, a one-stop B2B SaaS solution that connects pharmaceutical and medical device manufacturers with patients to deliver digital product and treatment support. Manufacturers receive their own branded product areas within a single unified app, enabling therapy monitoring, patient-reported outcomes (PRO) collection, pharmacovigilance reporting, and real-world evidence generation across more than 40 indications.
Is XO Life a public or private company?
XO Life is a private company. It is classified as venture growth investor backed and is currently operating.
When was XO Life founded?
XO Life was founded in 2017. It employs 11 to 50 people.
Where is XO Life based?
XO Life is headquartered in München, Germany, in the Europe region.
How does XO Life make money?
Two revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are digital Patient Support Services.
Who are XO Life's main competitors?
Broad incumbents on record are IQVIA and Veeva Systems. Direct peers are Medable, Science 37, Evidation Health, smartpatient (MyTherapy) and PatientsLikeMe. Emerging players are Castor, uMotif and Curebase.
Does XO Life have an API?
No public API is recorded for XO Life.
What industry is XO Life in?
XO Life's product category is Digital Health Patient Engagement Platform. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 51321 and its SIC code is 7372.